Altaba Inc. (NASDAQ:AABA) shares were trading lower by -1.18 percent ($-0.86) at $72.07 a piece in Monday’s session. It had closed the previous session at $72.93. AABA trades with a P/S ratio of 42.5. This compares with the industry’s 14.33 and the wider sector’s 6.05. A low price-to-sales ratio, typically less than 1.0, is considered a good value. Also, it has an estimated price-earnings (P/E) multiple of 135.98 and a trailing 12-month price-earnings (P/E) multiple of 38.5. Shares of AABA have uptrended 13.44% in the past three months, while the S&P 500 has moved 6.13% in that time. Altaba Inc. (AABA) has a market cap of $62.66 billion and over the last 12 months, Altaba Inc. (NASDAQ:AABA) has gone stronger by 76.34%. During the last 52 weeks, the (NASDAQ:AABA) price has been as high as $73.25 and as low as $38.24. Altaba Inc. earnings have declined with an annualized rate of -17.9% over the last 5 years. The average 1-year price target for Altaba Inc. (AABA) — averaging the work of different analysts — reveals a mean PT of $79.33/share. That’s a potential 10.07 increase relative to where Altaba Inc. (NASDAQ:AABA) has been trading recently. The current price is seen ranging between $71.92 and $73.12. There are brokerage firms with lower targets than the average, including one setting a price target of $65. And then on the other side of the spectrum one analyst entrenched in the bullish camp has a target as high as $99. The collective rating of 2 for Altaba Inc. (NASDAQ:AABA) also leans strongly towards the neutral end of the spectrum. Of the 1 analysts surveyed by Reuters that track AABA 0 of them rate its stock a hold. The other 1, though not evenly; between analysts who think you should buy Altaba Inc. versus those who think you should sell it. A 1 analysts rate it as either a buy or a strong buy, while0 believe that investors should either steer clear of AABA or, if they already own its stock, sell it. Nektar Therapeutics (NKTR) knifed -1.18 percent lower and now trades for $51.97. NKTR comes in with a P/S ratio of 32.55 that’s greater than 1, potentially implying that it could be expensive relative to the overall sector (5.36) and its peers (94.01). . . During the last 52 weeks, the price has been as high as $52.67 and as low as $11.41. Nektar Therapeutics (NASDAQ:NKTR) earnings have risen with a quarterly rate of 18.3% over the last 5 years. Shares of NKTR have increased 171.95% in the past three monthswhile the S&P 500 has gained 164.29% in that time. Nektar Therapeutics (NASDAQ:NKTR) has a market cap of $8.13 billion and over the last 12 months, NKTR has risen by 285.53%. The average 1-year price target for (NKTR) reveals an average price target of $42.14 per share. That’s a potential -18.91 fall from where (NASDAQ:NKTR) has been trading recently. There are brokerage firms with lower targets than the average, including one setting a price target of $31. And then on the other side of the spectrum one analyst entrenched in the bullish camp has a target as high as $50. The consensus recommendation — averaging the work of 11 analysts — of 1.6 for Nektar Therapeutics (NKTR) points to bullish case. Of the analysts surveyed by Reuters that track Nektar Therapeutics 1 of them rate its stock a hold. The other 10 are split, though not evenly, between analysts who think you should buy its stock versus those who think you should sell it. A 10 analysts rate it as either a buy or a strong buy, while 0 believe that investors should either steer clear of (NASDAQ:NKTR) or, if they already own its stock, sell it.




(adsbygoogle = window.adsbygoogle || []).push({});
